Risk of Infectious Complications in Patients Taking Glucocorticosteroids

Andreas E. Stuck, Christoph E. Minder, and Felix J. Frey

From the Medizinische Poliklinik and Institut für Sozial- und Präventivmedizin, University of Berne, Switzerland

The association between corticosteroid therapy and subsequent infections was calculated by pooling data from 71 controlled clinical trials. The overall rate of infectious complications was 12.7% in the 2,111 patients randomly allocated to systemic corticosteroids and 8.0% in the 2,087 controls (relative risk [RR], 1.6; 95% confidence interval [CI], 1.3–1.9; P < .001). The risk of infection was particularly high in patients with neurologic diseases (RR, 2.8; 95% CI, 1.9–4.3; P < .001) and less pronounced in patients with intestinal (RR, 1.4; 95% CI, 1.1–1.7; P = .02), hepatic (RR, 1.4; 95% CI, 0.9–2.3; P = .25), and renal (RR > 1; P = .03) diseases. The rate was not increased in patients given a daily dose of <10 mg or a cumulative dose of <700 mg of prednisone. With increasing doses the rate of occurrence of infectious complications increased in patients given corticosteroids as well as in patients given placebo, a finding suggesting that not only the corticosteroid but also the underlying disease state account for the steroid-associated infectious complications observed in clinical practice.

Corticosteroids in pharmacologic doses are commonly used to inhibit the immunologic network [1, 2]. As a consequence one might expect that the resistance to a wide variety of bacterial, viral, protozoal, and fungal agents is depressed, as was clearly demonstrated by numerous investigations in animals [3–5]. The effect of corticosteroids on the rate of infection was shown to depend upon many variables, including the dosage of the steroid and the resistance of the animal. These observations in animals were in accordance with the clinical impression of an increased rate of infections in patients treated with glucocorticoids.

Toxicologic studies in animals allow in many but not all instances for the prediction of potential adverse effects of a drug in humans and for the establishment of the underlying mechanism for such unwanted effects. However, such studies cannot provide a quantitative estimate of the rate of occurrence of a given adverse effect in humans. This might also be true for corticosteroids. For instance, a large number of the investigations dealing with the enhancement of the susceptibility to infectious agents were performed in so-called steroid-sensitive species, such as rodents [3–5], whereas humans belong to the group of steroid-resistant species [1]. The dosages of corticosteroids given to animals cannot be compared with those given to patients, because virtually all animal species investigated metabolize corticosteroids much faster and exhibit a different binding to plasma proteins than do humans [6–8]. Furthermore, some disease states, such as the nephrotic syndrome, Crohn’s disease, alcoholic cirrhosis, structural bronchopulmonary diseases, rheumatic diseases, multiple sclerosis, cerebrovascular diseases, and cranial trauma, which have been or are being treated with corticosteroids, are considered to predispose to the development of infectious diseases [9–16]. Thus, the clinical evidence of an increased rate of infectious complications in patients given corticosteroids has to be considered with caution, and only the analysis of controlled trials may allow demonstration of a causal and quantitative relationship between therapy with corticosteroids and appearance of infections.

Therefore, we examined the association between corticosteroid therapy and subsequent infectious diseases by pooling data from controlled clinical trials in which patients were randomized to treatment with or without systemic corticosteroids. In order to establish whether the risk of infectious complications was dose dependent, we calculated the association between daily doses or cumulative doses of prednisone and the rate of infections.
Methods

In the present investigation results of previous reports were combined and analyzed. This technique is designated meta-analysis [17, 18].

Selection criteria. A review of the English-language literature in which patients were assigned to receive systemic corticosteroids or nonsteroid therapy for at least 3 days was performed. For that purpose a MEDLINE computer search was supplemented by consultation with reviews, textbooks, and experts in the fields of hepatology, gastroenterology, pneumology, neurology, nephrology, and rheumatology and by review of references in all the trials found. The trials were analyzed according to a predetermined protocol.

Only controlled studies were included; studies in which adrenocorticotropin hormone was administered or in which systemic corticosteroid therapy was combined with cytostatic or other immunosuppressive agents were excluded. Trials in which patients were given antibacterial, antiviral, antifungal, or antiprotozoal agents were excluded, except when prophylactic isoniazid only was given. Studies were also excluded if the number of patients allocated to the treatment or placebo group was not indicated, if not enough information was given to estimate the dosage and duration of therapy, or if adverse effects were inadequately discussed (see below).

With regard to crossover studies, only data from the first arm of the study were included. No attempt was made to supplement data through personal communication. Eventually, 71 trials were included [19–90] for the final meta-analysis. A list of 58 relevant publications excluded from the final analysis can be obtained from the authors.

Complications. For analysis of nonlethal infectious complications, trials with inadequate discussion of adverse effects (i.e., not mentioned at all, not clearly enumerated for each treatment group, or too vaguely described) were excluded. If complications of therapy were described but an infection was not specifically mentioned, the paper was included on the assumption that no infectious complication occurred. For the analysis of lethal infectious complications, only trials specifying the causes of death were included. An infection was considered lethal if it was the main cause and not just a contributing cause of death. If all patients survived the trial, it was evident that no lethal infectious complication occurred.

Dosage and duration of therapy. Duration was measured as the number of days; if it varied among the patients in any study, the median duration was estimated. Steroid dosage was expressed in prednisone-equivalent milligrams [90] and evaluated in two ways—either as a cumulative dose or as a mean daily dose (cumulative dose divided by duration). If a trial included children, only adult dosage was considered for analysis. Thus, the conclusions derived from the present meta-analysis are only relevant for adult patients.

Statistical procedures. Statistical analysis for comparison of the number of infectious complications per 100 patients between patients with and without steroid therapy was performed according to three different methods: simple \( \chi^2 \) analysis of the pooled data, the Mantel-Haenszel technique of pooling individual \( \chi^2 \) values (with each study as a stratum), and the Mantel-Haenszel technique using Yates’s correction for \( \chi^2 \) values with small numbers [91]. If the \( P \) values derived by all three methods were on the same side of .05, only the highest is reported; if they were on both sides of .05, a range is given. The 95% confidence interval (CI) of the relative risk (RR) was calculated with use of the method described by Katz et al. [92].

In the analysis of the effect of steroid therapy adjusted for duration, the incidence (rate per 1,000 patients per 21 days) was calculated. The period of 21 days was chosen because it was the median duration of therapy in the 71 trials analyzed. The 95% CI and the \( P \) values were calculated by assuming a Poisson distribution of new cases, with the mean proportional to the number of patient-days observed [93]. For analysis of pooled trials with >20 infectious complications, an asymptotic 95% CI was calculated, while for analysis of pooled trials with <20 infectious complications the exact 95% CI was used. In addition, Wilcoxon’s rank sum test was used for comparison of subgroups of patients (as indicated in Results).

The analysis of the trials revealed that patients with a cumulative dose of <500 mg of prednisone or a mean dose of <10 mg of prednisone daily had no more infectious complications than did controls. For these subgroups of patients, a Type II error analysis was performed, again assuming a Poisson distribution [93].

Results

In all, 4,198 patients (1,969 male, 1,415 female, 814 unknown) were analyzed. It was not possible to ana-
lyze the infectious complications according to age and/or sex because not enough information was given in the reports of the trials. In order to estimate the age of all the patients investigated, the median value (range) of the median or mean age given in 46 trials was used: 46.1 years (25.8–74.5 years). The underlying diseases were: pulmonary diseases (364 patients), liver diseases (979), neurologic diseases (1,223), nephrotic syndrome (197), rheumatic diseases (167), inflammatory bowel diseases (807), and other diseases (461).

Among the 71 trials, 23 papers reported infectious complications. In 16 (70%) of these 23, the steroid group had more lethal and nonlethal infections than the controls, while in five trials (22%) the controls had more infections and in two (9%) an identical number of infections were reported in both groups. The overall rate of lethal and nonlethal infectious complications was 12.7% in the steroid-treated patients and 8.0% in the controls (P < .001) (table 1). Both lethal and nonlethal complications were increased in patients given corticosteroids, the relative risk being 2.6 (95% CI, 1.2–5.3) and 1.6 (1.3–1.9), respectively.

When separate analyses were performed for double-blind studies, studies using oral steroids, and studies using parenteral steroids, similar increased relative risks were found (table 1). When the 10 trials including both adults and children were excluded from analysis, similar statistically significant differences of infectious complications between the patients with and without steroids were observed (results not shown). In three investigations more than one infection per patient was possible, while in the remaining 68 trials, not more than one infection per patient was reported. When only these 68 trials were analyzed, similar differences were found between patients given steroids and controls (results not shown).

The relative risk in steroid-treated patients with a mean dose of <20 mg/d was 1.3 (95% CI, 1.0–1.6), as compared with 2.1 (1.3–3.6) in patients treated with a mean dose of 20–40 mg/d. When patients were given a mean daily dose >40 mg, no further increase in the relative risk was observed (table 2). This may be best explained by the shorter median duration of therapy in the patients given >40 mg of prednisone/d than in those given 20–40 mg/d (median 12 days, range 3–180 days vs. median 28 days, range 6–180

### Table 1. Analysis of lethal and nonlethal infectious complications in steroid-treated and control patients.

<table>
<thead>
<tr>
<th>Category of trial (no.)</th>
<th>No. of patients</th>
<th>No. of infectious complications/100 patients</th>
<th>P value</th>
<th>Relative risk (95% CI)</th>
<th>Incidence (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All (71)</td>
<td>2,111</td>
<td>2,087</td>
<td>.001</td>
<td>1.6 (1.3–1.9)</td>
<td>11.9 (10.4–13.3)</td>
<td>.001</td>
</tr>
<tr>
<td>Lethal (71)</td>
<td>2,111</td>
<td>2,087</td>
<td>.02</td>
<td>2.6 (1.2–5.3)</td>
<td>1.1 (0.7–1.6)</td>
<td>.009</td>
</tr>
<tr>
<td>Nonlethal (56)</td>
<td>1,665</td>
<td>1,669</td>
<td>.001</td>
<td>1.6 (1.3–1.9)</td>
<td>18.3 (16.0–20.6)</td>
<td>.001</td>
</tr>
<tr>
<td>Double-blind</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All (56)</td>
<td>1,551</td>
<td>1,507</td>
<td>.001</td>
<td>1.5 (1.3–1.9)</td>
<td>26.1 (22.8–29.3)</td>
<td>.001</td>
</tr>
<tr>
<td>Lethal (56)</td>
<td>1,551</td>
<td>1,507</td>
<td>.03</td>
<td>4.5 (1.3–15.8)</td>
<td>1.5 (0.8–2.3)</td>
<td>.01</td>
</tr>
<tr>
<td>Nonlethal (42)</td>
<td>1,405</td>
<td>1,433</td>
<td>.001</td>
<td>1.6 (1.3–1.9)</td>
<td>26.3 (22.9–29.7)</td>
<td>.001</td>
</tr>
<tr>
<td>Oral steroids*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All (52)</td>
<td>1,550</td>
<td>1,574</td>
<td>.003</td>
<td>1.4 (1.1–1.9)</td>
<td>7.3 (6.1–8.4)</td>
<td>.01</td>
</tr>
<tr>
<td>Lethal (52)</td>
<td>1,550</td>
<td>1,574</td>
<td>.02–.19</td>
<td>5.1 (1.1–23.1)</td>
<td>0.5 (0.2–0.8)</td>
<td>.02</td>
</tr>
<tr>
<td>Nonlethal (40)</td>
<td>1,131</td>
<td>1,184</td>
<td>.005</td>
<td>1.4 (1.1–1.9)</td>
<td>11.8 (9.9–13.6)</td>
<td>.007</td>
</tr>
<tr>
<td>Parenteral steroids*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All (13)</td>
<td>459</td>
<td>397</td>
<td>.001</td>
<td>2.3 (1.6–3.3)</td>
<td>484.1 (389.2–579.0)</td>
<td>.001</td>
</tr>
<tr>
<td>Lethal (13)</td>
<td>459</td>
<td>397</td>
<td>.15</td>
<td>2.0 (0.8–5.2)</td>
<td>67.8 (37.0–103.3)</td>
<td>.14</td>
</tr>
<tr>
<td>Nonlethal (12)</td>
<td>432</td>
<td>369</td>
<td>.004</td>
<td>2.4 (1.6–3.5)</td>
<td>424.2 (334.6–513.9)</td>
<td>.001</td>
</tr>
</tbody>
</table>

* Six trials could not be included in these two (oral or parenteral) categories because combined oral and parenteral therapy was administered in these trials.

† Number of infectious complications/(1,000 patients·21 d).
Table 2. Lethal and nonlethal infectious complications, according to mean daily steroid dose, median duration of therapy, and total cumulative steroid dose.

<table>
<thead>
<tr>
<th>Category of trial (no.)</th>
<th>No. of patients</th>
<th>Infectious complications/100 patients</th>
<th>P value</th>
<th>Relative risk (95% CI)</th>
<th>Incidence* (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Daily steroid dose (mg)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;20 (13)</td>
<td>657</td>
<td>689</td>
<td>17.8</td>
<td>14.2</td>
<td>.03-.07</td>
<td>1.3 (1.0-1.6)</td>
</tr>
<tr>
<td>20-40 (31)</td>
<td>652</td>
<td>621</td>
<td>6.8</td>
<td>3.2</td>
<td>.003</td>
<td>2.1 (1.3-3.6)</td>
</tr>
<tr>
<td>&gt;40 (27)</td>
<td>802</td>
<td>777</td>
<td>13.5</td>
<td>6.3</td>
<td>.005</td>
<td>2.1 (1.6-2.9)</td>
</tr>
<tr>
<td><strong>Duration of therapy (d)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;30 (43)</td>
<td>1,062</td>
<td>998</td>
<td>10.5</td>
<td>4.7</td>
<td>.001</td>
<td>2.3 (1.7-3.4)</td>
</tr>
<tr>
<td>≥30 (28)</td>
<td>1,049</td>
<td>1,089</td>
<td>15.0</td>
<td>11.0</td>
<td>.007</td>
<td>1.4 (1.1-2.3)</td>
</tr>
<tr>
<td><strong>Cumulative steroid dose (mg)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;500 (15)</td>
<td>254</td>
<td>247</td>
<td>0.8</td>
<td>0.8</td>
<td>.95</td>
<td>0.9 (0.1-6.6)</td>
</tr>
<tr>
<td>500-999 (19)</td>
<td>422</td>
<td>432</td>
<td>5.3</td>
<td>2.7</td>
<td>.05-.27</td>
<td>2.0 (1.0-3.9)</td>
</tr>
<tr>
<td>1,000-1,999 (13)</td>
<td>306</td>
<td>266</td>
<td>14.7</td>
<td>5.6</td>
<td>.02</td>
<td>2.6 (1.5-4.6)</td>
</tr>
<tr>
<td>≥2,000 (24)</td>
<td>1,119</td>
<td>1,142</td>
<td>17.9</td>
<td>12.1</td>
<td>&lt;.001</td>
<td>1.5 (1.2-1.8)</td>
</tr>
</tbody>
</table>

* Number of infectious complications/(1,000 patients · 21 d).

Discussion

The main purpose of a controlled clinical trial of corticosteroids is to establish the efficacy of such
therapy in a disease state. Special emphasis is therefore given to the assessment of the final therapeutic objective while the assessment of the adverse effects may be neglected. Thus, the report of the multiple adverse effects is usually much less detailed than the report of the impact of the corticosteroid on the underlying disease state. As a consequence, publications dealing with corticosteroid therapy might be qualitatively or quantitatively deficient with regard to the report of infectious complications. The qualitative deficiency in reporting infectious complications is clearly demonstrated by the fact that in <80% of the infections reported was the nature of the infectious disease, i.e., bacterial, viral, fungal, or protozoal, indicated.

On the basis of the data given in the publications of the controlled trials, it cannot be established whether all or only a fraction of the infectious com-

**Figure 1.** Double-logarithmic plot of the mean daily dose of prednisone vs. the median duration of therapy in 71 controlled trials. Each symbol represents one trial. The position of a symbol reflects the mean daily dose of prednisone (y axis) and the median duration of therapy prescribed (x axis) in a given trial. The closed squares (■) represent trials with a higher numerical incidence of infectious complications in the group of patients treated with prednisone than in the group of controls, whereas the open circles (○) represent trials without a higher incidence of infectious complications in patients given prednisone than in controls. The product of the duration of therapy times the daily dose is the cumulative dose of prednisone prescribed. The cumulative dose of 700 mg of prednisone is given by the oblique line. Note that all trials with a higher incidence of infections in patients given prednisone than in those given placebo are located above the isodose line of 700 mg, an indication that, independent of the dosage regimen, patients with a cumulative dose of <700 mg had no increased risk of infectious complications.

**Table 3.** Number of patients, daily prednisone dose, and duration of therapy in steroid-treated and control patients, according to the underlying disease state.

<table>
<thead>
<tr>
<th>Category of trials (no.)</th>
<th>No. of patients</th>
<th>Median daily steroid dose in mg (range)</th>
<th>Median duration of therapy in days (range)</th>
<th>Incidence* (95% CI)</th>
<th>P value</th>
<th>Steroid-treated</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intestinal (4)</td>
<td>386 421</td>
<td>18 (12-33)</td>
<td>195 (80-512)</td>
<td>19.4 (16.1-22.7)</td>
<td>.25</td>
<td>16.7 (13.5-19.9)</td>
<td></td>
</tr>
<tr>
<td>Hepatic (19)</td>
<td>494 485</td>
<td>40 (7-1,250)</td>
<td>28 (9-1,600)</td>
<td>3.9 (2.7-5.0)</td>
<td>.09</td>
<td>2.6 (1.7-3.5)</td>
<td></td>
</tr>
<tr>
<td>Neurologic (18)</td>
<td>633 590</td>
<td>90 (20-426)</td>
<td>12 (6-180)</td>
<td>166.4 (131-201.7)</td>
<td>&lt;.001</td>
<td>55.1 (34.7-75.5)</td>
<td></td>
</tr>
<tr>
<td>Pulmonary (14)</td>
<td>191 173</td>
<td>30 (13-40)</td>
<td>14 (7-180)</td>
<td>0.0 (0.0-7.8)</td>
<td>.99</td>
<td>0.0 (0.0-8.6)</td>
<td></td>
</tr>
<tr>
<td>Renal (2)</td>
<td>95 102</td>
<td>26 (11-41)</td>
<td>421 (112-730)</td>
<td>2.6 (0.8-4.6)</td>
<td>.01</td>
<td>0.0 (0.0-1.5)</td>
<td></td>
</tr>
<tr>
<td>Rheumatic (5)</td>
<td>89 78</td>
<td>8 (5-22)</td>
<td>42 (14-730)</td>
<td>0.0 (0.0-3.4)</td>
<td>.99</td>
<td>0.0 (0.0-4.9)</td>
<td></td>
</tr>
<tr>
<td>Other (9)</td>
<td>223 238</td>
<td>36 (18-1,926)</td>
<td>20 (3-84)</td>
<td>12.1 (4.5-30.2)</td>
<td>.95</td>
<td>12.9 (4.0-32.4)</td>
<td></td>
</tr>
</tbody>
</table>

* Number of infectious complications/(1,000 patients · 21 d).
Complications were reported. It is conceivable that only severe infectious complications and/or well-defined infections (for instance, pneumonia or herpes zoster) were reported, and minor and/or not well-defined entities such as urinary tract infection or flu-like syndromes were omitted. Thus, the quantitative results of the incidence of infectious complications derived from the present meta-analysis might indeed underestimate the true number of infections. Nevertheless, the differences in the incidence of infectious complications between patients on corticosteroids and controls are likely to be true, because underreporting can be expected in both groups of patients; overreporting of (expected) infectious complications in patients on corticosteroids can be excluded, because similar differences were observed when only the double-blind studies were analyzed (table 1).

Overall, 13% and 7% of the patients with and without corticosteroid therapy, respectively, had infectious complications. In most trials the patients were withdrawn from the study when the first infectious complication appeared. Since the point when the individual infectious complication occurred was often not indicated, it was not possible to correct the incidence of infectious complications according to the true duration of therapy. Therefore, the total duration of the study for the patients on placebo was probably slightly longer than for the group of patients given corticosteroids and thus increased the likelihood of infectious complications in control subjects. Furthermore, the true incidence of infectious complications in clinical practice (not under clinical study conditions) might be higher than in the present analysis because therapy is not usually withheld when the first infectious complication occurs.

The rate of infectious complications/[1,000 patients·21 d] increased from 22.6 in patients given 20–40 mg of prednisone/d to 150.7 in patients given >40 mg of prednisone/d (table 2). This dose dependency of the incidence of infectious complications was not paralleled by an increase in the relative risk, since the incidence of infections rose with increasing dosage in the corresponding control groups as well (table 2). This indicates that the underlying disease state, which dictates the dosage regimen of steroids, largely accounts for the variable and dose-dependent incidence of infectious complications observed in clinical practice.

Both the relative risk and the rate of infectious complications/[1,000 patients·21 d] increased with increasing cumulative steroid dose up to 1,999 mg and declined when a cumulative dose of ≥2,000 mg of prednisone was given (table 2). The decline of the relative risk of infectious complications at the highest cumulative steroid dose may be attributable to investigations in which a low dose of prednisone was prescribed for a very long period. Indeed, a mean daily steroid dose of <10 mg of prednisone for a long period was not associated with an increased relative risk of infectious complications (figure 1).

The incidence of infectious complications in patients treated with parenteral steroid was 484/[1,000 patients·21 d]. This rate has to be interpreted with caution because the median duration of the trials with parenteral treatment was <21 days. The reason for the much higher incidence of infectious complications in patients given parenteral compared with patients given oral steroids cannot be attributed to a low systemic availability of oral steroids [94] but rather to the high incidence of infectious complications in the corresponding (parenteral) controls and to the higher dose of corticosteroids prescribed in parenteral as opposed to oral form (results not shown).

The underlying disease state was a determinant of the incidence of infectious complications observed in control patients. Control patients with neurologic diseases had the highest incidence of infectious complications among the seven categories of trials (table 3). These subjects were the controls of the patients treated for a relatively short period with the highest daily dose of prednisone (table 3), a fact suggesting that the entire neurologic patient population was in a severe disease state that required high steroid doses and made the subjects highly susceptible to infectious complications. The absence of infectious complications in the control subjects of the prednisone-treated patients with pulmonary and renal diseases is probably best explained by the short duration of therapy and/or low dose of prednisone, a situation indicating a less-severe disease state than in patients with neurologic diseases (table 3). Alternatively, it is conceivable that neurologic diseases predispose patients to infectious complications more frequently than the other diseases and/or that the infectious complications were reported more accurately by the neurologists than by the physiciansconducting the other trials.

While the comparison of the incidence of infectious complications between control subjects with different underlying diseases is biased by the investigators who performed the studies, the comparison of the incidence between patients with and without
steroid therapy is not. When compared with the mean relative risk of infectious complications derived from all the studies analyzed (table 1), the risk in patients with intestinal, hepatic, renal, or other diseases (table 3) was roughly what was expected, while the risk in patients with neurologic diseases was abnormally high and in patients with pulmonary or rheumatic diseases, abnormally low. The threefold increase of the incidence of infectious complications in steroid-treated patients with neurologic diseases, compared with that in control patients with neurologic diseases (table 3), strongly suggests that this patient population exhibits an unusually high sensitivity to the induction of infectious complications by corticosteroids. However, since patients with neurologic diseases were given higher doses of prednisone than patients with other diseases (table 3), it cannot be decided whether the higher risk of complications was attributable to the higher steroid dosage or to a higher sensitivity to the adverse effects of steroids as a result of the underlying disease. Similarly, the absence of an increased risk of infectious complications in patients with pulmonary or rheumatic diseases might be attributable to the low dosage of prednisone, to the short duration of therapy, or to the underlying disease state (table 3).

The present analysis revealed no increased risk of infectious complications in patients given a daily dose of <10 mg or a cumulative dose of <700 mg of prednisone. It would be erroneous to conclude that the prescription of lower doses of prednisone is absolutely safe for the following reasons. As is true for all patients participating in controlled clinical trials, the patients considered in the present meta-analysis are only partly representative of the patients treated in clinical practice. For instance, in controlled clinical trials most patients have a single well-defined disease, whereas in clinical practice the situation is often more complicated. In clinical practice one might have to initiate therapy with prednisone in patients who are already suffering from an infection or who are immunocompromised, conditions that might have precluded the participation in a controlled trial with prednisone. Furthermore, certain states, such as renal failure, hepatic disease, old age, or concomitant drug therapy (e.g., ketoconazole or oral contraceptive steroids), decrease the metabolism of prednisolone [95-100] and therefore might increase the likelihood of infections even at doses below the threshold doses for increased risk of infections found in the controlled trials. Conversely, patients with an enhanced catabolism of the steroid because of induced microsomal liver enzymes by xenobiotics (mainly phenytoin, barbiturates, or rifampin) or because of hyperthyroidism exhibit less immunosuppressive effect — and as a corollary less infectious risk — from the same dose of prednisone than do patients with a normal steroid metabolism [101-103]. Thus, knowledge of the dose of prednisone below which no increased risk of infections was found in controlled trials is only meaningful information when it is used in conjunction with knowledge of the pretherapy susceptibility to infection and the metabolism of the steroid.

This meta-analysis demonstrates within the limits of the methods employed [16] that glucocorticoids increase the risk of lethal and nonlethal infectious complications, a result in accordance with uncontrolled observations in clinical practice. In addition, the analysis of the controlled trials reveals two new concepts that are of practical relevance: (1) the risk of prednisone therapy-associated infectious complications is dose dependent, with no increased risk in patients given a daily dose of <10 mg or a cumulative dose of <700 mg of prednisone; and (2) the risk of prednisone therapy-associated infectious complications is particularly high in patients with neurologic diseases and less pronounced in patients with intestinal, hepatic, or renal diseases, an indication that the susceptibility to infection is due not only to the prednisone therapy but also to the type and severity of the underlying disease.

References

5. Kass EH. Hormones and host resistance to infection. Bacteriological Reviews 1960;24:177-85
8. Frey BM, Sieber M, Mettler D, Gänger H, Frey FJ. Marked interspecies differences between humans and pigs in cy-
27. Evans JA, Morrison IM, Saunders KB. A controlled trial of prednisone, in low dosage, in patients with chronic air-
ways obstruction. Thorax 1974;29:401–6
77. Singleton JW, Law DH, Kelley ML Jr, Mekhjian HS, Sturdevant RAL. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979;77:870–82
102. Frey BM, Frey FJ. Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. Eur J Clin Invest 1984;14:1-6